Hoth Therapeutics Receives Protocol Approval For HT-001 Cancer Therapeutic; FDA Approved Trial Now Has Two Sites Approved With Additional Sites In Approval Process
Portfolio Pulse from Happy Mohamed
Hoth Therapeutics, Inc. (NASDAQ:HOTH) has received FDA approval for a protocol change in its Phase 2a clinical trial of HT-001, a cancer therapeutic. The trial will now be conducted at two approved sites, with additional sites in the approval process. The study will be completed in two parts, with the first part being an open-label cohort and the second part being a randomized, placebo-controlled, parallel Phase 2a dose-ranging study.
July 19, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Hoth Therapeutics has received FDA approval for a protocol change in its Phase 2a clinical trial of HT-001. This could potentially accelerate the trial process and bring the product to market sooner.
The FDA approval for a protocol change in the Phase 2a clinical trial of HT-001 is a positive development for Hoth Therapeutics. This could potentially accelerate the trial process and bring the product to market sooner, which could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100